49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
Showing 1 to 7 of 7 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900022934 | 2019-06-20 | 2019-05-04 | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus erythematosusin Study for the metabolic mechanism of Langchuangjing granule in the treatment of systemic lupus eryth ... | Systemic Lupus Erythematosus | Experimental group:Langchuangjing granule + Prednisone acetate tablets, Hydroxychloroquine;control group:Prednisone acetate tablets?Hydroxychloroquine;healthy control group:nothing; Experimental group:Langchuangjing granule + Prednisone acetatetablets, Hydroxychloroquine;control gr ... | Nanjing University of Chinese Medicine Affiliated Hospital | NULL | Pending | Both | Experimental group:20;control group:20;healthy control group:20; | Phase 1 | China | ||
| 2 | ChiCTR1800020286 | 2019-02-01 | 2018-12-22 | Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus erythematosus Clinical evaluation of the application of Langchuangjing granule in the treatment of systemic lupus ... | Efficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a clinical evaluation Efficacy and safety of Langchuangjing granule in the treatment of systemic lupus erythematosus: a cl ... | Systemic Lupus Erythematosus | Group 2:Langchuangjing granule + Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.;Group 1:Prednisone acetate tablets, hydroxychloroquine and other Western medicines for 12 weeks.; Group 2:Langchuangjing granule + Prednisone acetatetablets, hydroxychloroquineand other Western medi ... | Nanjing University of Chinese Medicine Affiliated Hospital | NULL | Pending | Both | Group 2:40;Group 1:20; | I (Phase 1 study) | China | ||
| 3 | NCT03262727 (ClinicalTrials.gov) | September 1, 2017 | 24/8/2017 | The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in He ... | The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol ... | Systemic Lupus Erythematosus;Arthritic Psoriasis;Psoriasis;Inflammatory Bowel Diseases | Drug: BMS-986165;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | Bristol-Myers Squibb | NULL | Completed | 18 Years | 40 Years | Female | 49 | Phase 1 | United States |
| 4 | ChiCTR-INR-17011495 | 2017-05-25 | 2017-05-26 | Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic sy Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorva ... | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of pr ... | Primary mild to moderate systemic systemic lupus erythematosus | Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.; Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and wee ... | The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Te ... | NULL | Recruiting | Both | Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30; | China | |||
| 5 | JPRN-jRCTs071180052 | 26/12/2014 | 15/03/2019 | Control of steroid-associated osteonecrosis of the femoral head in SLE patients | Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial corticosteroid treatment in patients with systemic lupus erythematosus - None Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial cortico ... | systemic lupus erythematosus;D008180 | Objectives take three below candidate drugs for the prevention for at least 3 months after the initial corticosteroid treatment. 1. Clopidogrel Bisulfate (Plavix) Taking a dose of 300mg once daily on the first day, and a dose of 75mg once daily on subsequent days. 2. Pitavastatin Calcium (LIVALO) Taking a dose of 2mg once daily. 3. Tocopherol Acetate (Juvela) Taking a dose of 100mg three times daily (total of 300mg daily). Objectives take three below candidate drugs for the prevention for at least 3 months after the initi ... | Nakashima Yasuharu | NULL | Recruiting | >= 20age old | Not applicable | Both | 150 | Phase 2 | Japan |
| 6 | JPRN-UMIN000008230 | 2014/08/01 | 22/06/2012 | Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial corticosteroid treatment in patients with systemic lupus erythematosus Clinical trial for the control of osteonecrosis of the femoral head secondary to the initial cortico ... | Systemic lupus erythematosus | Objectives take three below candidate drugs for the prevention for at least 3 months after the initial corticosteroid treatment. 1. Clopidgrel Bisulfate (Plavix) Taking a dose of 300mg once daily on the first day, and a dose of 75mg once daily on subsequent days. 2. Pitavastatin Calcium (LIVALO) Taking a dose of 2mg once daily. 3. Tocopherol Acetate (Juvela) Taking a dose of 100mg three times daily (total of 300mg daily). Objectives take three below candidate drugs for the prevention for at least 3 months after the initi ... | Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 150 | Phase 2 | Japan | |
| 7 | EUCTR2005-001391-12-IT (EUCTR) | 28/07/2005 | 23/03/2006 | A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patients A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Paralle ... | A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 for Injection Administered Subcutaneously to Systemic Lupus Erythematosus SLE patients A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Paralle ... | Treatment of active SLE patients who are concurrently undergoing a regimented program of decreased steroid use. MedDRA version: 6.1;Level: PT;Classification code 10042945 Treatment of active SLE patients who are concurrently undergoing a regimented program of decreased s ... | Product Name: Edratide Acetate Product Code: TV-4710 Product Name: Edratide Acetate Product Code: TV-4710 Product Name: Edratide Acetate Product Code: TV-4710 Product Name: Edratide Acetate Product Code: TV-4710 Product Name: Edratide Acetate Product Code: TV-47 ... | TEVA | NULL | Not Recruiting | Female: yes Male: yes | 260 | Hungary;Germany;United Kingdom;Spain;Italy |